Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Magenta Therapeutics closes $50mm Series B round

Executive Summary

Magenta Therapeutics Inc. (curative stem cell transplantation) raised $50mm through an oversubscribed Series B round from GV (lead; formerly Google Ventures) and all existing investors including Atlas Venture, Third Rock Ventures, Partners Innovation Fund, Access Industries, Casdin Capital, Be The Match BioTherapies, and undisclosed crossover investors. The company also announced an in-licensing from Novartis AG, and a partnership with Be The Match BioTherapies, a division of bone marrow and umbilical cord transplantation organization National Marrow Donor Program/Be The Match.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies